News
Compelling Phase 1 safety and efficacy data for FAP-Dox (AVA6000) with preliminary evidence of efficacy in salivary gland ...
FAP-EXd (AVA6103) demonstrates tumor growth inhibition and durable complete responses in multiple therapy-resistant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback